logo-loader
viewC4X Discovery Holdings plc

Full interview: C4X Discovery fully cashed up and sees big potential for its 'blockbuster molecules'

C4X Discovery Holdings plc's (LON:C4XD) Clive Dix speaks to Proactive London's Andrew Scott following the news they've raised around £6.6mln to strengthen its balance sheet amid ongoing licensing discussions for its early-stage drug candidates.

While expressing regret for the level at which the funds were raised, Dix says they need to have a good level of cash in the bank while partnering discussions are taking place.

On the current valuation of the business, Dix says: ''It's a bargain for anyone who knows and understands the healthcare sector well''.

''For people that don't they may get shocked that it takes time, but if you're a slightly longer term investor who understands the healthcare space this is one of the best companies to invest in''.

''I've been in this business a long time and I look at all the others ... I put my money behind this and have on a regular basis''.

Quick facts: C4X Discovery Holdings plc

Price: 16 GBX

AIM:C4XD
Market: AIM
Market Cap: £9.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings plc named herein, including the promotion by the Company of C4X Discovery Holdings plc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: 'Momentum building' within C4X Discovery portfolio as it...

C4X Discovery Holdings plc's (LON:C4XD) Clive Dix updates Proactive London's Andrew Scott on progress across the firm's portfolio. He says they're very confident of delivering deals in the near future. Dix adds licensing discussions with potential partners for two of its early-stage drugs,...

on 2/10/19

2 min read